Scholarlink

Purpose <p>Antibacterial host defense peptides (HDPs) are naturally occurring peptides that combat multidrug-resistant infections effectively. The high selectivity and specificity of peptides combat the side effects of synthetic drugs. In the past, our lab developed an HDP called DP1 (Design Peptide 1). Preliminary investigations demonstrated the efficacy of DP1 in both in silico and in vitro settings displaying substantial anti-aggregating and curative characteristics, thus positioning DP1 as a promising therapeutic option for various diseases. However, the bio-distribution pattern of DP1 remains unexplored. This study aims to elucidate the bio-distribution of DP1 and DP1 encapsulated in Coumarin 6-labeled Poly (lactic-co-glycolic acid) nanoparticles (DCPN) in serum, liver, kidney and brain.</p> Methods <p>DP1 was encapsulated in DCPN to improve its bioavailability and was prepared using solvent extraction method. Various fluorescent quantification techniques and LC–MS were used to study the bio-distribution of DP1 in biological systems.</p> Results <p>Results indicated that DP1 could traverse the blood–brain barrier without altering the structural integrity of tissues. Due to the limited lifespan of peptides in biological systems, we explored a secure and efficient delivery system via DCPN. </p> Discussion <p>Bio-distribution analysis of nanoformulated DCPN and FITC- DP1 (F-DP1) in serum and brain tissue revealed a higher and more prolonged presence of DP1 in the biological system with DCPN, suggesting its potential for treating chronic disorders that require extended drug exposure. At the same time, F-DP1 has been found to be suitable for immediate therapeutic intervention. Future studies into the pharmacokinetics and pharmacodynamics will help consolidate DP1's potential as a therapeutic agent.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biodistribution Studies of FITC Labelled DP1 and DP1 Encapsulated Coumarin-6 PLGA Nanoparticles in Murine Model

  • 期刊论文

  • 发表日期：

    2025年5月20日

查看全文
  • Satvika Sharma,
  • Mahima Chugh,
  • Sheetal Sharma,
  • Mayank Maan,
  • Devinder Kumar Dhawan,
  • Avneet Saini

摘要

Purpose

Antibacterial host defense peptides (HDPs) are naturally occurring peptides that combat multidrug-resistant infections effectively. The high selectivity and specificity of peptides combat the side effects of synthetic drugs. In the past, our lab developed an HDP called DP1 (Design Peptide 1). Preliminary investigations demonstrated the efficacy of DP1 in both in silico and in vitro settings displaying substantial anti-aggregating and curative characteristics, thus positioning DP1 as a promising therapeutic option for various diseases. However, the bio-distribution pattern of DP1 remains unexplored. This study aims to elucidate the bio-distribution of DP1 and DP1 encapsulated in Coumarin 6-labeled Poly (lactic-co-glycolic acid) nanoparticles (DCPN) in serum, liver, kidney and brain.

Methods

DP1 was encapsulated in DCPN to improve its bioavailability and was prepared using solvent extraction method. Various fluorescent quantification techniques and LC–MS were used to study the bio-distribution of DP1 in biological systems.

Results

Results indicated that DP1 could traverse the blood–brain barrier without altering the structural integrity of tissues. Due to the limited lifespan of peptides in biological systems, we explored a secure and efficient delivery system via DCPN.

Discussion

Bio-distribution analysis of nanoformulated DCPN and FITC- DP1 (F-DP1) in serum and brain tissue revealed a higher and more prolonged presence of DP1 in the biological system with DCPN, suggesting its potential for treating chronic disorders that require extended drug exposure. At the same time, F-DP1 has been found to be suitable for immediate therapeutic intervention. Future studies into the pharmacokinetics and pharmacodynamics will help consolidate DP1's potential as a therapeutic agent.